List of Quillichew Er drug patents

Quillichew Er is owned by Nextwave Pharms.

Quillichew Er contains Methylphenidate Hydrochloride.

Quillichew Er has a total of 9 drug patents out of which 0 drug patents have expired.

Quillichew Er was authorised for market use on 04 December, 2015.

Quillichew Er is available in tablet, extended release, chewable;oral dosage forms.

Quillichew Er can be used as a method for treating a subject having adhd, said method comprising orally administering to said subject a racemic methylphenidate chewable tablet as claimed, a method of providing a subject with a therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet as claimed, a method of providing a subject with therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet according to claim 1.

The generics of Quillichew Er are possible to be released after 14 August, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8202537 NEXTWAVE PHARMS Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(4 years from now)

US8287903 NEXTWAVE PHARMS Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US9844544 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(10 years from now)

US11103495 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(10 years from now)

US9545399 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(10 years from now)

US11103494 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(10 years from now)

US8999386 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(10 years from now)

US10857143 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(10 years from now)

US9295642 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(10 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 04 December, 2015

Treatment: A method of providing a subject with a therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet as claimed; A method for treating a subject having adhd, said method comprising orally administering to said subject a racemic methylphenidate chewable tablet as claimed; A method of providing a subject with therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet according to claim 1

Dosage: TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

How can I launch a generic of QUILLICHEW ER before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in